Voyageur Pharmaceuticals Ltd. (TSX.V:VM) USA (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has signed a cost plus manufacturing agreement with Alberta Veterinarian Laboratories Ltd. ("AVL"). This agreement allows Voyageur to begin the process of formulating and testing our new products with AVL and prepare for production and sales.  AVL is committing mixing and fill lines for Voyageur's production. Voyageur and AVL are working jointly to create high quality health products for the clinical radiology market. AVL will be responsible for all Active Pharmaceutical Ingredients ("API") formulation, bottling and packaging. Voyageur will focus on country by country regulatory approvals, marketing, sales, logistics, distribution and supply-chain management to enter the North American market and  new markets worldwide.

Voyageur will be finalizing the product lines and implementing final testing of products prior to full production start up. The pre-production phase is estimated to be completed in Q4 2021 and entails packaging design, fill line design & testing, laboratory batch testing, client batch testing, forward sales and marketing.

AVL recently completed construction in January 2021, of its modern and state of the art Good Manufacturing Practice ("GMP") pharmaceutical manufacturing facility. AVL received its Drug Establishment Licence (DEL) and have passed the inspection and are in full compliance for manufacturing, testing, distribution, importing API and labelling of powders, solutions, suspensions, pastes, ointments. Voyageur is excited to work with AVL and to continue to move Voyageur towards cash flow and full integration of its barium radiographic product lines and barium quarry.

About Alberta Veterinarian  Laboratories Ltd.

Alberta Veterinary Laboratories Ltd. Is a family owned pharmaceutical manufacturing company that produces multiple veterinarian products under the AVL and Solvet brands, including oral liquids, suspensions, pour-on topical and oral powders. AVL manufactures the popular human nasal rinse RhinoRinse.  The products are manufactured in a state-of-the-art facility located in Calgary, Alberta.. AVLprovides quality animal health products to thousands of farmers, vets and pet owners across Canada. With the original inception of Ivermectin Pour-On for Cattle, AVL provides a Canadian manufacturing alternative to a popular anti-parasitic drug that saved cattle producers millions per year. Since the initial offering of Ivermectin Pour-On, AVL expanded its portfolio of animal health products to encompass companion animals and other farm animals, human pharmaceutical. AVL is an innovative company that searches new solutions to old problems.

About Voyageur

Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM.  Voyageur is focused on the development of drugs related to the minerals barite and iodine as API minerals. The near-term focus is developing barium and iodine radiographic contrast products. Voyageur’s goal is to initially generate positive cash flow from operations using third party pharmaceutical manufacturers. Ultimately, Voyageur plans to build the required infrastructure to become 100% self-sufficient with all manufacturing of drugs and API minerals. Voyageur owns a 100% interest in three barium sulfate (barite) projects including its 100% owned Frances Creek barium sulfate property and also owns interests in an iodine, lithium and bromine heavy mineral brine project located in Utah, USA. Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field by controlling all primary input costs under the slogan of: "From the Earth to the Bottle".

For further information, please contact:

Ron Love, CFO, Cell: (403) 818-6086, This email address is being protected from spambots. You need JavaScript enabled to view it.

Brent Willis, CEO, This email address is being protected from spambots. You need JavaScript enabled to view it.

www.voyageurpharmaceuticals.ca

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the timing for the completion of the pre-production phase, AVL's ability to manufacture Voyageur's products and Voyageur's ability to obtain the regulatory approvals and sell those products. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties.  There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information.  A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com.  Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.